Evidence map›Paper›PMID 31861119›Full record

ArticlePharmaceutics2019

Site-Specific

Dave Lumen, Simo Näkki, Surachet Imlimthan, Elisavet Lambidis, Mirkka Sarparanta, Wujun Xu, Vesa-Pekka Lehto, Anu J Airaksinen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Molecular pharmaceutics · 2023
    Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Dave LumenDepartment of Chemistry, Radiochemistry, University of Helsinki, FI-00014 Helsinki, Finland.
Simo NäkkiDepartment of Applied Physics, University of Eastern Finland, FI-70221 Kuopio, Finland.
Surachet ImlimthanDepartment of Chemistry, Radiochemistry, University of Helsinki, FI-00014 Helsinki, Finland.ORCID 0000-0003-2520-2146
Elisavet LambidisDepartment of Chemistry, Radiochemistry, University of Helsinki, FI-00014 Helsinki, Finland.
Mirkka SarparantaDepartment of Chemistry, Radiochemistry, University of Helsinki, FI-00014 Helsinki, Finland.ORCID 0000-0002-2956-4366
Wujun XuDepartment of Applied Physics, University of Eastern Finland, FI-70221 Kuopio, Finland.
Vesa-Pekka LehtoDepartment of Applied Physics, University of Eastern Finland, FI-70221 Kuopio, Finland.
Anu J AiraksinenDepartment of Chemistry, Radiochemistry, University of Helsinki, FI-00014 Helsinki, Finland.ORCID 0000-0002-5943-3105
University of Helsinki · FIUniversity of Eastern Finland · FI

Funding

Academy of Finland #298481, 314412 and 318422
6 · The paper itself

Abstract

Polyethylene glycol (PEG) has been successfully used for improving circulation time of several nanomaterials but prolonging the circulation of porous silicon nanoparticles (PSi NPs) has remained challenging. Here, we report a site specific radiolabeling of dual-PEGylated thermally oxidized porous silicon (DPEG-TOPSi) NPs and investigation of influence of the PEGylation on blood circulation time of TOPSi NPs.

Indexed as

click chemistryIEDDAindium-111porous siliconSPECT

Identifiers

PMID31861119
PMCPMC6969933
OpenAlexW2994698531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.